Novartis Eyes Fourth Approval For Cosentyx
An nr-axSpA okay will boost Swiss major's biggest seller
Executive Summary
As Novartis files Cosentyx for non-radiographic axial spondyloarthritis, it is becoming increasingly clear that psoriasis will not be the blockbuster's revenue growth driver going forward.
You may also be interested in...
Novartis Confident Cosentyx Can Keep Competition At Bay
The Swiss major's biggest seller rose 12% in the second quarter and while COVID-19 had an impact, and competition is on the rise, Cosentyx is still outpacing the market overall in psoriasis, while rheumatology should drive future growth.
Novartis Q4 Preview: Launches Likely To Deliver
Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.
Novartis Targets Ten Indications For Cosentyx
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.